Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Gentronix Unveils New Corporate Identity and Website

Published: Tuesday, March 26, 2013
Last Updated: Tuesday, March 26, 2013
Bookmark and Share
Gentronix offers GreenScreen® HC and BlueScreen™ HC assays.

Gentronix has revealed a new corporate identity and re-designed website. The new identity has been developed to reflect how the company has evolved into a mainstream provider of early screening in vitro genetic toxicology assays, and mechanistic follow-up, to a range of business sectors including pharmaceuticals, chemicals, agrochemicals, flavours fragrances and taste enhancers, and the personal care and consumer product industries.

In addition to classical in vitro early screening assays, such as the Ames bacterial mutation reversal and Micronucleus tests, Gentronix offers their proprietary GreenScreen® HC and BlueScreen™ HC assays.

The company also supports clients in the development of de-risking strategies and carrying out further assays to determine the mechanism and causes of positive genotox screening results.

As such, Gentronix has a wealth of knowledge and experience in the field and this is reflected in the new website at which hosts content on the science of genotoxicity, regulations for each industry sector, screening procedures, as well as links to an extensive range of peer reviewed papers.

John Nicholson, CEO at Gentronix, comments, “In recent years we have greatly diversified our range of genotoxicity screening product and service offerings. We also provide advice on dealing with positive results and are able to offer a variety of further assays and strategies to help understand the mechanism of genotoxicity. This updating of our corporate identity has been undertaken to better reflect this. These are exciting times for Gentronix, and we feel that the new identity and website helps us to build on our strong foundations to move the business forward.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gentronix Announces Strategic Intent to Provide GLP Services
Strategic intention to offer regulatory genotox assays.
Tuesday, March 04, 2014
Gentronix Awarded Grant of £147,552 by MRC and Technology Strategy Board
Company awarded grant from the Biomedical Catalyst programme for an epigenetic based screening assay feasibility study.
Thursday, December 20, 2012
Gentronix Signs First Japanese Contracted Screening Collaboration with Kowa
Gentronix Ltd. has announced the company's first contracted screening project in Japan, with a major Japanese pharmaceutical manufacturer, Kowa Company, Ltd.
Thursday, October 04, 2012
Gentronix Expands Specialist Sales Team in US and Europe
Expansion of sales teams with the appointments of Dorothy Zelent and Simon Johns.
Friday, February 17, 2012
Gentronix Partner with BioQuanta
The agreement covers the commercialization of the Mitoxis® functional metabolomics platform from BioQuanta.
Thursday, November 10, 2011
Gentronix and Apredica Ally to Create Predictive-Toxicology Service
Joint service offering expected to increase drug development success and the safety of new drugs on the market.
Thursday, June 11, 2009
Improved In Vitro Genotoxicity Testing to Reduce Animal Testing
In conjunction with the University of Manchester, Gentronix has been granted a research award of £133,024.
Thursday, August 10, 2006
Gentronix Secures R&D Award
The two-year grant will provide Gentronix with two scientists, cell culture facilities, and supporting laboratory instrumentation at its Manchester Incubator Core Technology Facility premises.
Tuesday, April 11, 2006
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos